Lucentis approved for visual impairment due to retinal vein occlusion

Ranibizumab is derived from the same antibody as the cancer drug bevacizumab (Avastin).
Ranibizumab is derived from the same antibody as the cancer drug bevacizumab (Avastin).

Lucentis (ranibizumab) can now be prescribed to treat visual impairment due to macular oedema secondary to retinal vein occlusion. The VEGF-targeting antibody fragment was previously licensed for neovascular (wet) age-related macular degeneration and visual impairment due to diabetic macular oedema.

The randomised, double-blind BRAVO and CRUISE studies tested ranibizumab in patients with visual impairment due to macular oedema secondary to branch RVO (n=397) and central RVO (n=392), respectively. Participants received either ranibizumab for 12 months or sham injections for 6 months followed by ranibizumab for the next 6 months. Mean increase in visual acuity at 6 months was significantly greater in the ranibizumab-only group than the sham/ranibizumab group in both studies (p<0.0001).

Overall, 60.3% of ranibizumab patients in BRAVO and 50.8% of those in CRUISE experienced a gain of 15 or more letters by 12 months, compared with 43.9% and 33.1%, respectively of sham/ranibizumab patients.

Dosing for the new indication is the same as for diabetic macular oedema: 0.5mg by monthly intravitreal injection.

View Lucentis drug record

Further Information: Novartis Phamaceuticals

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

NICE recommends aflibercept for AMD

NICE recommends aflibercept for AMD

New guidance from NICE approves the use of aflibercept...

Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab (Lucentis) can now be prescribed in the...

NICE amends ranibizumab guidance

NICE amends ranibizumab guidance

NICE has overturned its original decision to reject...

Lucentis gains diabetic indication

Lucentis - a new macular degeneration treatment

Novartis has launched Lucentis (ranibizumab) for the...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases